生产企业：PersonGen BioTherapeutics (Suzhou) Co., Ltd.
UTAA-09 is a CD19-targeted universal off-the-shelf UCAR-Vδ1T cell therapy developed by PersonGen BioTherapeutics. It received NMPA clinical trial approval in April 2025, becoming the world's first approved universal off-the-shelf CD19-UCAR-Vδ1T cell product.
UTAA-09 is a CD19-targeted universal off-the-shelf UCAR-Vδ1T cell therapy developed by PersonGen BioTherapeutics. It received NMPA clinical trial approval in April 2025, becoming the world's first approved universal off-the-shelf CD19-UCAR-Vδ1T cell product.
UTAA-09 is a CD19-targeted universal chimeric antigen receptor (CAR) Vδ1T cell therapy. Unlike conventional CAR-T therapies based on αβ T cells, UTAA-09 utilizes Vδ1T cells — a subset of gamma-delta T cells that are naturally resident in human tissues — as the cellular platform. These cells possess strong homing ability that enables penetration of the solid tumor microenvironment. The product is manufactured using a CMC large-scale process enabling massive ex vivo expansion and cryopreservation of Vδ1T cells while retaining off-the-shelf properties, eliminating the need for patient-specific autologous manufacturing.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
